A national data supplier provided palivizumab claims for Medicaid and commercial health plans across the nation from January 2019 through December 2019.
Health plans deny 40% of palivizumab prescriptions for premature infants born between 29 and 36 weeks gestation.
One in every four prescriptions is denied for infants who should qualify for coverage under standard insurance policies.
Read Report Card